Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Cancer Med. 2020 May;9(10):3455-3462. doi: 10.1002/cam4.3012. Epub 2020 Mar 24.
Whether prognosis differs between lung acinar predominant adenocarcinoma (ACN) and papillary predominant adenocarcinoma (PAP) patients remains controversial. Furthermore, the appropriate surgical plan for each subtype is undetermined.
Data of stage I ACN or PAP patients from 2004 to 2015 were retrospectively reviewed by SEER*Stat 8.3.5. The primary outcome was overall survival (OS) and lung cancer specific survival (LCSS).
1531 patients (PAP, 484; ACN, 1047) were included. ACN patients had better OS (P = .001) and LCSS (P = .003) than PAP patients. Among stage I ACN patients, lobectomy with mediastinal lymph node dissection (Lob) (P = .001) or segmentectomy (Seg) (P = .003) provided a better OS than wedge resection (Wed). And ACN patients who received Lob had a equivalent LCSS, compared to those who received Seg (P = .895). For patients with PAP in stage I, those who received Lob tended to have a better prognosis than that received Seg (HR of OS, 0.605, 95% CI: 0.263-1.393; HR of LCSS, 0.541, 95% CI: 0.194-1.504) or Wed (HR of OS, 0.735, 95% CI: 0.481-1.123; HR of LCSS, 0.688, 95% CI: 0.402-1.180).
Among patients with lung adenocarcinoma in stage I, those with ACN have a better OS and LCSS than that with PAP. For patients with stage I ACN, Seg and Lob, rather than Wed, seem to be an equivalent treatment choice; however, Seg is the prior option because it could preserve more lung function than Lob. For patients with PAP, Lob tends to be a better choice than Wed and Seg, although the prognostic difference between them is nonsignificant.
肺腺泡为主型腺癌(ACN)和乳头为主型腺癌(PAP)患者的预后是否存在差异仍存在争议。此外,每种亚型的适当手术方案尚未确定。
通过 SEER*Stat 8.3.5 回顾 2004 年至 2015 年期间 I 期 ACN 或 PAP 患者的数据。主要结局是总生存(OS)和肺癌特异性生存(LCSS)。
共纳入 1531 例患者(PAP:484 例;ACN:1047 例)。ACN 患者的 OS(P =.001)和 LCSS(P =.003)均优于 PAP 患者。在 I 期 ACN 患者中,肺叶切除术加纵隔淋巴结清扫术(Lob)(P =.001)或节段切除术(Seg)(P =.003)的 OS 优于楔形切除术(Wed)。并且接受 Lob 的 ACN 患者的 LCSS 与接受 Seg 的患者相当(OS 的 HR,0.605,95%CI:0.263-1.393;LCSS 的 HR,0.541,95%CI:0.194-1.504)。对于 I 期 PAP 患者,接受 Lob 的患者的预后优于接受 Seg(OS 的 HR,0.605,95%CI:0.263-1.393;LCSS 的 HR,0.541,95%CI:0.194-1.504)或 Wed(OS 的 HR,0.735,95%CI:0.481-1.123;LCSS 的 HR,0.688,95%CI:0.402-1.180)。
在 I 期肺腺癌患者中,ACN 患者的 OS 和 LCSS 优于 PAP 患者。对于 I 期 ACN 患者,Seg 和 Lob 似乎是 Wed 的等效治疗选择,而不是 Lob;然而,Seg 是首选,因为它比 Lob 能保留更多的肺功能。对于 PAP 患者,Lob 似乎是 Wed 和 Seg 的更好选择,尽管它们之间的预后差异无统计学意义。